scholarly journals Proximal-type epithelioid sarcoma - Case report

2013 ◽  
Vol 88 (3) ◽  
pp. 444-447 ◽  
Author(s):  
Luciana Mendes dos Santos ◽  
Lisiane Nogueira ◽  
Christiane Yuri Matsuo ◽  
Carolina Talhari ◽  
Monica Santos
Keyword(s):  
Young Adults ◽  
Case Report ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Distant Metastasis ◽  
Clinical Course ◽  
Epithelioid Sarcoma ◽  
Aggressive Clinical Course ◽  
Middle Aged Adults ◽  
Rhabdoid Features

Epithelioid sarcoma, first described by Enzinger in 1970, is a rare soft-tissue sarcoma typically presenting as a subcutaneous or deep dermal mass in distal portions of the extremities of adolescents and young adults. In 1997, Guillou et al. described a different type of epithelioid sarcoma, called proximal-type epithelioid sarcoma, which is found mostly in the pelvic and perineal regions and genital tracts of young to middle-aged adults. It is characterized by a proliferation of epithelioid-like cells with rhabdoid features and the absence of a granuloma-like pattern. In this paper we present a case of proximal-type epithelioid sarcoma with an aggressive clinical course, including distant metastasis and death nine months after diagnosis.

Epithelioid sarcoma of the neck: case report

2009 ◽  
Vol 123 (S31) ◽  
pp. 113-116 ◽  
Author(s):  
Y Ueda ◽  
H Chijiwa ◽  
T Nakashima
Keyword(s):  
Case Report ◽  
Soft Tissue ◽  
Local Recurrence ◽  
Neck Dissection ◽  
Distant Metastasis ◽  
Epithelioid Sarcoma ◽  
Malignant Tumour ◽  
Final Diagnosis ◽  
History Of ◽  
Growing Mass

AbstractEpithelioid sarcoma is an aggressive, malignant tumour of the soft tissue which tends to arise in proximity to large tendons and aponeuroses. We report the case of a patient presenting with an epithelioid sarcoma arising in the neck. A 56-year-old man was referred with a three-year history of a sensory disorder as well as a slowly growing mass in his right neck. The patient underwent resection of the tumour by means of a conservative neck dissection. The final diagnosis, based on the histological and immunohistochemical findings, was epithelioid sarcoma. Radiotherapy was performed after the operation. The post-operative course was uneventful, and there was no local recurrence or distant metastasis.

Efficacy and safety of anlotinib plus TQB2450 in patients with advanced soft tissue sarcoma: A multicenter, single armed, phase 1b trial.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 11547-11547
Author(s):  
Jiayong Liu ◽  
Zhengfu Fan ◽  
Wei Guo ◽  
Tian Gao ◽  
Shu Li ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Kinase Inhibitor ◽  
Soft Part ◽  
Epithelioid Sarcoma ◽  
Objective Response ◽  
Progression Free Survival ◽  
Efficacy And Safety ◽  
Phase 1B ◽  
Anthracycline Chemotherapy

11547 Background: Anlotinib, a multitargeted tyrosine kinase inhibitor, had been prove to be effective for the treatment of advanced or metastatic soft tissue sarcoma(STS) faild anthracycline chemotherapy. With the lack of prospective data of combination of PDL-1 inhibitor and antiangiogenic agent, we designed a phase 1b study to investigated the efficacy and safety of anlotinib plus TQB2450 in patients with STS. Methods: Eligible patients (age 18-70, ECOG 0-1, with histopathologically confirmed advanced STS, at least one measurable lesion according to RECIST 1.1, and previously received front-line anthracycline chemotherapy) were included and received anlotinib (12mg qd, D1-14, 21d/cycle) plus TQB2450 (1200 mg, IV, D1, 21d/cycle) until disease progression or intolerable toxicities.The primary endpoint was objective response rate (ORR), secondary endpoints included safety, overall survival (OS), progression-free survival (PFS), disease control rate (DCR). Results: From January 2019 to January 2021, 30 pts were enrolled1, 12 alveolar soft part sarcoma and 18 others (7 synovial sarcoma, 4 leiomyosarcoma, 5 undifferentiated pleomorphic sarcoma, 1 fibrosarcoma and 1 epithelioid sarcoma). ORR by RECIST was 36.7%, DCR was 83.3%, 11/30 pts had PR, 14/30 (46.7%) had SD, 5/30 (16.7%) PD. Median PFS was 9.6 m in all pts and 4.9m. in non-ASPS, respectively. Median OS in non-ASPS was 10.27m, while mOS in all pts and both mPFS and mOS in ASPS had not been reached. Notably, to ASPS pts, ORR was 75%, and DCR was 100%. The most common 1-2 grade treatment-related adverse reaction (TRAE) was hypothyroidism (19/30,63.3%)，hypercholesterolemia (16/30, 53.3%) and hypertriglyceridemia (16/30, 53.3%), the most common ≥3 grade TRAEs were hypertriglyceridemia (3/30, 10%). 6 SAE (20%) occurred, including 2 pneumothorax, 1 Immune associated hapatic injury, 1 hypotension, 1 Immune myocarditis and 1 diabetic ketoacidosis. Conclusions: The combination of anlotinib and TQB2450 showed promising activity in second-line treatment of advanced STS, especially in ASPS, with well tolerance and acceptable toxicity.

Follicular Lymphoma With a Burkitt Translocation—Predictor of an Aggressive Clinical Course: A Case Report and Review of the Literature

2004 ◽  
Vol 128 (2) ◽  
pp. 210-213 ◽  
Author(s):  
Peter M. Voorhees ◽  
Kathryn A. Carder ◽  
Scott V. Smith ◽  
Lanier H. Ayscue ◽  
Kathleen W. Rao ◽  
...  
Keyword(s):  
Case Report ◽  
Follicular Lymphoma ◽  
Clinical Course ◽  
Lymphoblastic Leukemia ◽  
Initial Diagnosis ◽  
Indolent Lymphoma ◽  
Review Of The Literature ◽  
Cell Type ◽  
Aberrant Expression ◽  
Aggressive Clinical Course

Abstract Follicular lymphoma is an indolent lymphoma characterized by the (14;18) translocation, which leads to aberrant expression of Bcl-2. Translocations involving 8q24 are most commonly associated with Burkitt lymphoma and result in c-Myc overexpression. We report a case of follicular lymphoma of predominant small cleaved-cell type (grade 1) associated with both a t(14;18)(q32;q21) and a t(8;22)(q24;q11). The 8q24 translocation predicted an aggressive clinical course, as the lymphoma transformed into acute lymphoblastic leukemia within a year of initial diagnosis. Routine cytogenetic analysis is recommended at initial diagnosis of follicular lymphoma to better identify abnormalities that may predict prognosis and influence therapy.

Challenges of Clinical Management of Adolescent and Young Adults With Bone and Soft Tissue Sarcoma

2018 ◽  
Vol 24 (6) ◽  
pp. 301-306 ◽  
Author(s):  
Andrea Ferrari ◽  
Patrizia Gasparini ◽  
Jonathan Gill ◽  
Richard Gorlick
Keyword(s):  
Young Adults ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Clinical Management ◽  
Adolescent And Young Adults

Metastatic Canine Medullary Thyroid Carcinoma: A Case Report

1980 ◽  
Vol 17 (3) ◽  
pp. 323-330 ◽  
Author(s):  
G. G. Long ◽  
R. M. Clemmons ◽  
H. Heath
Keyword(s):  
Case Report ◽  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Distant Metastasis ◽  
Clinical Course ◽  
Medullary Carcinoma ◽  
Neoplastic Tissue ◽  
Medullary Thyroid ◽  
Biochemical Alterations ◽  
Mitotic Figures

A medullary carcinoma of the thyroid in a dog first became evident because of a distant metastasis. The histologic characteristics of the tumor differ from those previously reported in dogs in that this tumor was highly malignant; anaplasia and mitotic figures were common. The diagnosis was substantiated by radioimmunoassay for calcitonin. Serotonin and 5-hydroxytryptophan also were elevated in the neoplastic tissue. The relation of the biochemical alterations to the clinical course was not clear.

scholarly journals Maffucci syndrome and soft tissue sarcoma: a case report

2009 ◽  
Vol 6 (1) ◽  
Author(s):  
Fernando César Toniazzi Lissa ◽  
Juliana Sonego Argente ◽  
Geórgia Nunes Antunes ◽  
Franciani de Oliveira Basso ◽  
Janara Furtado
Keyword(s):  
Case Report ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Maffucci Syndrome

Pazopanib-induced mixed liver injury in a patient with soft-tissue sarcoma, but without the UGT1A1*28 mutation: a case report

2020 ◽  
Author(s):  
Manabu Hayashi ◽  
Kazumichi Abe ◽  
Masashi Fujita ◽  
Atsushi Takahashi ◽  
Yasuyuki Kobayashi ◽  
...  
Keyword(s):  
Case Report ◽  
Soft Tissue ◽  
Liver Injury ◽  
Soft Tissue Sarcoma

scholarly journals The metabolomic scent of cancer disease progression in soft tissue sarcoma: A case report

2019 ◽  
Vol 34 (2) ◽  
pp. 205-209 ◽  
Author(s):  
Gianmaria Miolo ◽  
Debora Basile ◽  
Andrea Carretta ◽  
Davide Adriano Santeufemia ◽  
Agostino Steffan ◽  
...  
Keyword(s):  
Case Report ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Disease Progression ◽  
Real Time ◽  
Time Analysis ◽  
Cancer Disease ◽  
Non Invasive ◽  
Real Time Analysis ◽  
Volatile Organic

Background: The purpose of this case report is to describe the potential that metabolomics breath analysis may have in cancer disease monitoring. The advances in mass spectrometry instrumentation allow the accurate real-time analysis of volatile metabolites exhaled in the breath. The application of such non-invasive devices may provide innovative and complementary monitoring of the physio-pathological conditions of cancer patients. Case presentation: A 59-year-old Caucasian woman with spindle cell malignant mesenchymal sarcoma of the presacral region started a first-line therapy with non-pegylated liposomal doxorubicin and ifosfamide associated with pelvic radiant treatment. After two cycles of chemotherapy plus radiotherapy, a significant pulmonary disease progression was reported. Thus, a second-line therapy with trabectedin was administered. However, after only two cycles of treatment a re-staging computed tomography scan reported further cancer disease progression of the target pulmonary lesions as well as occurrence of new satellite bilateral nodules. Real-time analysis of breath exhaled volatile organic compounds, performed by select ion flow tube mass spectrometry (SIFT-MS) during the follow-up of the patient, showed a specific metabolic pattern not observed in the breath of other soft tissue sarcoma patients who achieved clinical benefit from the treatments. Conclusions: This case report revealed the importance of the non-invasive real-time volatile organic compounds breath analysis to distinguish individual specific chemo-resistance phenotypes among soft tissue sarcoma patients. Such observation seems to suggest that breath metabolomics may be particularly useful for monitoring cancer disease progression in soft tissue sarcoma patients where only cost-effective diagnostic tools, such as positron emission tomography and computed tomography, are available.

Sign in / Sign up

Export Citation Format

Share Document